Inovio CEO sees 2025 to be ‘transformational year’

Inovio (INO) highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings, with President and Chief Executive Officer Dr. Jacqueline Shea stating: “Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for patients suffering from a devastating rare disease and delivering on the promise of DNA medicines. Our top priorities for the coming year are the submission of our biologics license application for INO-3107 and preparing to expedite the launch of the product commercially, should it be approved. We also look forward to making progress with our pipeline through collaborations and other potential strategic opportunities.”